Aprogen ⁤Poised to Benefit from EMA Biosimilar Policy Shift

Aprogen, an antibody drug development company, anticipates ⁢significant advantages from a potential policy change by the European Medicines Agency (EMA) regarding biosimilar approvals.The EMA is considering a policy that could allow ⁤marketing authorization⁤ for biosimilars based ⁤on quality analysis ⁤data ⁢and Phase 1⁤ clinical trial data, possibly eliminating the need for Phase 3⁤ clinical trials.

The EMA initiated a public consultation on this proposed‍ policy, which began on April 1st and will continue through ⁤September 30th.‍ Following the consultation, the EMA is expected to announce its decision on whether to implement the new policy. This shift could⁤ significantly alter the landscape for biosimilar development and approval in Europe.

Potential Cost and Time Savings

Aprogen believes this policy change would⁣ especially benefit mid-sized biosimilar companies like itself. The elimination of Phase 3 trials could result in⁤ cost savings ⁤ranging from tens of billions of won to as much as 200 billion won per product. Moreover, it could shorten the development timeline by an estimated ⁤two to four years.

According to Aprogen, this could disrupt the current biosimilar market, which is ⁤largely dominated by global corporations. The company claims to possess the technology to manufacture biosimilars of drugs like Humira, Herceptin, and ⁤Rituxan at significantly lower costs than its competitors.

Aprogen’s Manufacturing Capabilities

Aprogen reports achieving significant cost reductions in the manufacturing of ‍biosimilars. For example, ⁢its Humira biosimilar production involves⁣ large-scale 15,000-liter cultivation, achieving a cost⁢ less than one-fifth of competitors’ costs. Similarly, its ⁢Herceptin⁣ biosimilar boasts a manufacturing cost approximately one-quarter or less compared to other manufacturers.Though, the company⁣ states that the cost of Phase 3 clinical trials has been a significant barrier, with Humira biosimilar trials costing around 60 billion won, Herceptin biosimilar trials around 140 billion won, and potential⁣ Kitruda biosimilar trials exceeding 240 billion ⁤won. The EMA policy change would alleviate this ⁤financial burden and accelerate the ⁣path to market.

U.S.FDA Considerations

Currently, the U.S. Food and Drug management (FDA) ⁣requires Phase 3 clinical trials for biosimilar approvals.However, Aprogen noted that FORMYON, a German biosimilar company, recently completed a Phase III trial for a Kitruda biosimilar after consultations with the FDA and is now preparing for⁣ marketing authorization based on quality‍ analysis data ⁢and Phase 1⁢ clinical data.

Aprogen’s Strategy

An Aprogen⁢ official stated that the company is reviewing its ongoing Phase ⁤III clinical trial for its herceptin biosimilar considering the⁣ potential policy changes by the EMA and the FDA. The company intends to apply for marketing authorization as soon as possible. “We will apply for the item ⁤permits,”‍ the official said.

Regarding a Kitruda biosimilar, ‍the official added, “In the‍ case of⁤ Kitruda Biosimilars, we have not started full-scale clinical development due to the enormous clinical trials of more than 240 billion won, even though we have secured cost-competitive cell lines and production technologies.” The official expressed‍ confidence in the potential market success of its biosimilars.

Aprogen and the EMA’s Biosimilar Policy Shift: A Q&A

This article will answer common‍ questions about Aprogen’s potential‍ benefits from a possible policy change by the European⁣ Medicines Agency (EMA) ⁤regarding biosimilar approvals.⁣ We’ll examine the potential financial and time-saving⁢ impacts of this change and discuss Aprogen’s strategy.

What is a Biosimilar?

A biosimilar is a biological product that is highly similar to an already approved biological medicine (the reference product) and has no clinically meaningful differences in terms of safety, purity, and potency. Unlike generic ⁤drugs, which are copies of small-molecule drugs, biosimilars are complex molecules made in living cells.

What is the EMA and What Policy Change is Being Considered?

The ⁤European Medicines Agency (EMA) is a regulatory agency of the European Union⁣ responsible for the scientific evaluation, supervision, and safety monitoring of ⁣medicines in the EU. The⁤ EMA is considering a policy change that could allow marketing authorization for biosimilars based on‍ quality analysis data and phase 1 clinical trial data. This change could⁣ perhaps eliminate the need for Phase 3 clinical trials.

How Could⁤ the EMA Policy Change Benefit Companies Like Aprogen?

The policy change could significantly benefit mid-sized biosimilar companies like Aprogen. Eliminating Phase 3 trials could lead to substantial cost savings, potentially ranging from tens of billions of‍ won to as much⁣ as 200 billion won per product. Furthermore, it‍ could accelerate the growth timeline by an estimated two to four years, enabling these companies⁢ to bring ⁣their products to⁣ market faster.

What are Aprogen’s Manufacturing Capabilities?

Aprogen reports that it has achieved significant cost reductions in biosimilar manufacturing:

Humira Biosimilar: Production ⁣using 15,000-liter cultivation, achieving⁢ costs less than one-fifth of‍ competitors.

Herceptin Biosimilar: Manufacturing costs approximately one-quarter or less than other manufacturers.

The company highlights that the high costs of Phase 3⁤ clinical trials pose a⁣ significant barrier. phase 3 trials are estimated to cost:

Humira biosimilar trials: Approximately 60 billion won

Herceptin biosimilar trials: Approximately 140 billion won

* Potential ⁢Kitruda ⁣biosimilar trials: Exceeding 240 billion won

How Does the FDA’s Requirements Compare?

The⁤ U.S. Food and Drug Administration (FDA) currently requires Phase 3 clinical trials for biosimilar approvals. Aprogen notes that FORMYON, a German biosimilar company, recently completed a Phase III trial for a Kitruda biosimilar after consultations with the FDA, and is preparing ‍for marketing authorization based on quality analysis data and Phase 1 clinical data. This suggests that while the FDA currently requires Phase 3 Trials, its approach may be informed by its consultations with other biosimilar companies.

What is Aprogen’s Strategy Regarding the⁢ Potential Policy Change?

Aprogen is reviewing its ongoing ⁢Phase III clinical trial for its herceptin biosimilar, considering potential policy changes by both the EMA and the FDA. the company intends to apply for marketing authorization as soon as possible.⁣ The official expressed confidence in the potential market success of its biosimilars if the EMA policy shift came into effect.

Regarding⁣ a Kitruda biosimilar,⁢ Aprogen has not⁣ started full-scale clinical development due to the enormous costs of Phase 3 clinical trials. However, the company has secured cost-competitive cell lines and production technologies.

What are the key Differences in Trial Costs?

The cost associated with each trial are as follows:

| Drug | Approximate Phase 3 Trial Cost (in Billion won) |

| ——————- | ⁣———————————————– |

| Humira⁢ Biosimilar | 60 |

| Herceptin Biosimilar | 140 ⁤ ⁢ ⁢ ⁢ |

| Kitruda Biosimilar | > 240 ‍ ⁤ ⁣ ⁤ ‍ |